UPDATE: Credit Suisse On Acumen Outperform Initiation: Firm Highlights Differentiated Amyloid Beta Approach For Alzheimer's Disease With ACU193 Targeting Oligomers; Warns On Non-Targeting Approach Towards Plaque & Expects 15% Probability Of Success